CTIC — CTI Biopharma Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- $1.20bn
- $1.26bn
- $53.95m
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:10 AM
Brief: Cti Biopharma Reports Q4 Loss Per Share Of $0.20
Brief: Cti Biopharma Files Prospectus Supplement Relating To Offering Of Shares Of Common Stock Of Up To $50 Million Under Sales Agreement - SEC Filing
Brief: CTI Biopharma Corp Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Brief: CTI BioPharma Reports Q3 Loss Per Share Of $0.15
CTI BioPharma: Rises after starting cancer drug marketing application submission
Brief: CTI Biopharma Initiates Rolling Submission Of NDA For Pacritinib
CTI BioPharma surges on plan to submit marketing application for cancer drug
Brief: CTI Biopharma To Submit A New Drug Application For The Accelerated Approval Of Pacritinib
Brief: CTI Biopharma Reports Second Quarter 2020 Financial Results
U.S. STOCKS ON THE MOVE-Gilead, Virgin Galactic, General Electric
CTI BioPharma up on enrolling first patient in COVID-19 drug study
Brief: CTI Biopharma Enrolls First Patient In Covid-19 Pre-Vent Phase 3 Trial
Brief: Cti Biopharma Reports First Quarter 2020 Financial Results
U.S. STOCKS ON THE MOVE-Tanker operators, oil and gas companies, Caterpillar
U.S. STOCKS ON THE MOVE-Southern Co, Apple, American Express, Zoom Video, U.S. banks
CTI BioPharma: Surges after starting late-stage trial on severe COVID-19 patients
Brief: Cti Biopharma Announces Initiation Of Phase 3 Pre-Vent Study Evaluating Pacritinib In Hospitalized Patients With Severe Covid-19
Brief: Cti Biopharma Corp - Received Letter Stating Co Not In Compliance With Nasdaq Listing Rule